“There is a high unmet need for patients with EGFR-resistant mCRC and NSCLC cancers as patients currently have limited therapeutic options,” said Kirsten Drejer, Chief Executive Officer of Symphogen. “We are pleased by the advancement of Sym004 into these new studies, and the Phase 1 dose-finding study in Japan of Sym004 that was initiated in late 2013, and we look forward to generating clinical data with this compound.”
Out-licensed worldwide by Symphogen to Merck in September 2012, Sym004 was the subject of data presentations at the 2013 and 2014 ASCO Annual Meetings in Chicago, IL. At these meetings, Sym004 reported Phase 2 proof-of-concept data in squamous cell carcinoma of the head & neck (SCCHN) and in metastatic colorectal cancer that signaled clinical activity and were supportive of the proposed mechanism of action, respectively.
About SYM004
Sym004 is comprised of two antibodies that are not only designed to block ligand binding, receptor activation and downstream signaling but are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.
Sym004 was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.
For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: + 45 22 10 99 59
E-mail: kd@symphogen.com
Annes Associates
Shari Annes
Phone: 650-888-0902
E-mail: sannes@annesassociates.com
Consilium Strategic Communications
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
Phone: +44 20 3709 5702
E-mail: symphogen@consilium-comms.com